Fig. 1

Bioinformatics analyses reveal that RBM15 is a potential methyltransferase of the lncRNA CBR3-AS1 and is involved in radioresistance in patients with NSCLC. A Enriched and specific m6A peak distribution of CBR3-AS1 transcripts was predicted using the online SRAMP tool. The red arrows indicate m6A modification sites with very high confidence in the m6A enrichment peaks at nucleotide positions 448–532 of the lncRNA CBR3-AS1 transcripts. B Diagram showing the position of m6A motifs with very high confidence within the CBR3-AS1 transcripts. C Correlation between methyltransferase and CBR3-AS1 expression estimated by Pearson correlation analysis. D Box plot of RBM15 expression in patients with NSCLC and normal controls. The difference was estimated by Wilcoxon rank-sum test. E Kaplan–Meier survival curves of patients with NSCLC who received radiotherapy stratified by RBM15 mRNA expression in TCGA-NSCLC cohort. The OS difference was estimated by log-rank test, and HR and 95% CIs were calculated using univariate Cox model. F Interaction probabilities of RBM15 with CBR3-AS1 as estimated using RNA–protein interaction prediction. G Representative immunohistochemistry images of the RBM15 protein in radioresistant and radiosensitive NSCLC samples. H Box plot of RBM15 expression in radioresistant and radiosensitive NSCLC patients. The difference was estimated by Wilcoxon rank-sum test. I Sankey diagram showing the flow/change of high- and low-RBM15 protein levels in radioresistant and radiosensitive NSCLC samples. J–K Kaplan–Meier survival curves of 133 NSCLC tumor specimens stratified by RBM15 protein levels as detected using immunohistochemistry. The OS difference was estimated by log-rank test, and HR and 95% CIs were calculated using univariate Cox model